

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Masure, et al

Serial No. : 09/869,079

Art Unit:

Filed : June 20, 2001

Examiner:

For : HUMAN AKT-3

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, Washington, D.C. 20231 on

February 14, 2002

(Date of Deposit)

Myra H. McCormack

(Name of applicant, assignee, or Registered Representative)

Myra McCormack

(Signature)

February 14, 2002

(Date of Signature)


Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this
information may not be prior art, and/or to prove that this



information may not be enabling for the teaching purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached);
or

☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
☐ Please charge Deposit Account No. 10-0750/ /
the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ There are no listed references which are not in the English language.


☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1458/MHM. This form is submitted in triplicate.

Respectfully submitted,


Myra H. McCormack
Reg. No. 36602
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-6932
DATED: February 14, 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	09/869079
Filing Date	06/20/2001
First Named Inventor	Masure, et. al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1458

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ³
		Office ³	Number ⁴	Kind Code ⁵				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner 's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	1	AHMED, N.N., et al., "Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase." Proc. Natl Acad Sci USA (1997) 94:3627-3632.	
	2	ALESSI, D.R., et al., "Mechanism of activation and function of protein kinase B." Current Opinion Gen. Dev. (1998) 8:55-62.	
	3	ALLESSI, D.R., et al., "Mechanism of activation of protein kinase B by insulin and IGF-1" EMBO Journal (1996) 15:6541-6551.	
	4	ALESSI, D.R., et al., "3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTP61 kinase." Curr. Biol. (1997) 7:776-789.	
	5	ALTOMARE, D.A., et al., "Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene." Oncogene (1995) 11:1055-1060.	
	6	ALTSCHUL, S.F., et al., "Basic Local Alignment Search Tool," J. Mol. Biol. (1990) 215:403-410.	
	7	BELLACOSA, A., et al., "Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications" Oncogene (1993) 8:745-754.	
	8	BELLACOSA, A., et al., "Molecular Alterations Of The Akt2 Oncogene In Ovarian And Breast Carcinomas," Int. J. Cancer (1995) 64:280-285.	


Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	09/869,079
Filing Date	6/20/2002
First Named Inventor	Masure
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1458

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	9	CHENG, J.Q., et al., "AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas," Proc. Natl. Acad. Sci. USA (1992) 89:9267-9271.	
	10	BRODBECK, D., et al., "A Human Protein Kinase B with Regulatory Phosphorylation Sites in the Activation Loop and in the C-terminal Hydrophobic Domain", The Journal of Biological Chemistry 1999 Vol. 274:9133-9136	
	11	CHIEN, C., et al., "The two-hybrid system: A method to identify and clone genes for proteins that interact with a protein of interest," Proc. Natl. Acad. Sci. USA 1991 Vol. 88:9578-9582	
	12	COFFER, P.J., et al., "Protein kinase B (c-akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation", Biochem Journal 1998 Vol 335:1-13	
	13	COFFER, P.J., et al., "Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families," Eur. J. Biochem. 1991 201:475-481	
	14	COHEN, P., et al., "PDK1, one of the missing links in insulin signal transduction?", FEBS Letters 1997 410:3-10	
	15	COONEY, M., et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human c-myc Gene in Vitro," Science 1988 Vol 241:456-459	
	16	CROWDER, R.J., et al., "Phosphatidylinositol 3-Kinase and Akt Protein Kinase Are Necessary and Sufficient for the Survival of Nerve Growth Factor-Dependent Sympathetic Neurons," Journal of Neuroscience 1998 Vol 18 (8):2933-2943	
	17	DATTA, S.R., et al., "Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery," Cell. 1997 Vol. 91:231-241	
	18	DAVIS, P.D., et al., "Inhibitors of Protein Kinase C. 2. Substituted Bisindolylmaleimides with Improved Potency and Selectivity," J. Med. Chem., 1992 Vol. 35:994-1001	
	19	del PESO, L., et al., "Interleukin-3-Induced Phosphorylation of BAD Through the Protein Kinase Akt", Science 1997 Vol. 278:687-689	
	20	DELCOMMENNE, M., et al., "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase," Proc. Natl. Acad. Science USA (1998) Vol. 95:11211-11216	
	21	BEAL, P.A., et al., "Second Structural Motif for Recognition of DNA by Oligonucleotide-Directed Triple-Helix Formation," Science (1991) 251:1360-1363	
	22	DUDEK, H., et al., "Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt," Science (1997) 275:661-665	
	23	EVES, E.M., et al., "Akt, a Target of Phosphatidylinositol 3-Kinase, Inhibits Apoptosis in a Differentiating Neuronal Cell Line," Molecular and Cellular Biology (1998) Vol. 18 (4):2143-2152	
	24	FRISCH, S.M., et al., "Integrins and anoikis," Current Opinion in Cell Biol (1997) 9:701-706	
	25	FRISCH, S.M., et al., "Disruption of Epithelial Cell-Matrix Interactions Induces Apoptosis," Journal of Cell Biology (1994) Vol. 124:619-626	
	26	HANKS, S.T., et al., "The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification(1) FASEB Journal (1995) Vol. 9:576-596	
	27	HEMMING, B.A., "Akt Signaling: Linking Membrane Events to Life and Death Decisions," Science (1997) 275:628-630	
	28	HENG, H.H., et al., "High-resolution mapping of mammalian genes by in situ hybridization to free chromatin," Proc Natl Acad Sci USA (1992) 89:9509-9513	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	09/869,079
Filing Date	6/20/2002
First Named Inventor	Masure
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1458

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	29	HENG, H.Q., et al., "Modes of DAPI banding and simultaneous in situ hybridization," Chromosoma (1993) 102:325-332	
	30	JONES, P.F., et al., "Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily," Proc Natl Acad. Sci. USA (1991) 88:4171-4175	
	31	KAUFFMANN-ZEH, A., et al., "Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB", Nature (1997) 385:544-548	
	32	KENNEDY, S.G., et al., "The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal", Genes & Development 1997 11:701-713	
	33	KHWAJA, A., et al., "Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway," The EMBO Journal (1997) Vol. 16 (10) 2783-2793	
	34	KONISHI, H., et al., "Molecular Cloning of Rat Rac Protein Kinase α And β and their association with protein kinase C ξ **", Biochemical and Biophysical Research Communications (1994) Vol. 205 (1) 817-825	
	35	KONISHI, H., et al., "Molecular Cloning and Characterization of a New Member of the RAC Protein Kinase Family: Association of the Pleckstrin Homology Domain of three types of RAC protein kinase with protein Kinase C subspecies and $\beta\gamma$ Subunits of G Proteins", Biochemical and Biophysical Research Communications (1995) Vol. 216 (2) 526-534	
	36	KULIK, G., et al., "Antiapoptotic Signalling by the Insulin-Like Growth Factor I Receptor, Phosphatidylinositol 3-Kinase, and Akt", Molecular and Cellular Biology, (1997) Vol. 17 (3) 1595-1606	
	37	LEE, J.S., et al., "Complexes formed by (pyrimidine) _n (purine) _n DNAs on lowering the pH are three-stranded," Nucleic Acids Research (1979) Vol 6:3073-3091	
	38	LENNON, G., et al., "The I.M.A.G.E. Consortium: an Integrated Molecular Analysis of Genomes and Their Expression," Genomics (1996) 33:151-152	
	39	LOCKHART, D.J., et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays," Nature Biotechnology (1996) Vol. 14:1675-1680	
	40	MARTE, B.M., et al., "R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways," Current Biology (1996) Vol. 7:63-70	
	41	MASURE, S., et al., "Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3," Eur. J. Biochem. (1999) Vol. 265:353-360	
	42	MEIER, R., et al., "Mitogenic Activation, Phosphorylation, and Nuclear Translocation of Protein Kinase B β ", Journal of Biological Chemistry (1997) Vol. 272 (48) 30491-30497	
	43	MEREDITH, J.E., "The Extracellular Matrix as a Cell Survival Factor," Molecular Biology of the Cell," (1993) Vol. 4 953-961	
	44	MITELMAN, F., "A breakpoint map of recurrent chromosomal rearrangements in human neoplasia," Nature Genetics (1997) 15:417-474	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Application Number	09/869,079
Filing Date	6/20/2002
First Named Inventor	Masure
Group Art Unit	
Examiner Name	
Attorney Docket Number	JAB-1458

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	45	MUSACCHIO, A., "The PH domain: a common piece in the structural patchwork of signalling proteins," Trends Biochem Sci 1993 18:343-348	
	46	NAKATANI, K., "Identification of a Human Akt3 (Protein Kinase B γ) Which Contains the Regulatory Serine Phosphorylation Site," Biochemical and Biophysical Research (1999) Vol. 257:906-910	
	47	NAKATANI, K., "Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines," Journal of Biological Chemistry (1999) Vol. 274:21528-21532	
	48	OKANO, H., "Myelin Basic Protein Gene and the Function of Antisense RNA in its Repression in Myelin-Deficient Mutant Mouse," Journal of Neurochemistry (1991) Vol. 56:560-567	
	49	PHILPOTT, K.L., "Activated Phosphatidylinositol 3-Kinase and Akt Kinase Promote Survival of Superior Cervical Neurons," Journal of Cell Biology (1997) Vol. 139 (3) 809-815	
	50	SHEPHERD, P.R., et al., "Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling," Biochem. Journal (1998) Vol. 333:471-490	
	51	STAAL, S.P., "Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma," Proc. Natl. Acad. Sci USA (1987) Vol. 84:5034-5037	
	52	STOKOE, D., et al., "Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B," Science (1997) Vol. 277:567-570	
	53	WALKER, K.S., et al., "Activation of protein kinase B β and γ isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B α ," Biochem Journal (1998) Vol. 331:299-308	
	54	KONISHI, H., et al., "Molecular Cloning and Characterization of a New Member of the RAC Protein Kinase Family: Association of the Pleckstrin Homology Domain of Three Types of RAC Protein Kinase With Protein Kinase C Subspecies and $\beta\gamma$ Subunits of G Proteins," Biochemical and Biophysical Research Comm, (1995) Vol. 216:526-534	
	55	MASURE, S., et al., "Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3," Eur. Journal Biochem. (1999) Vol. 265:353-360	
	56	NAKATANI, K., et al., "Identification of a Human Akt3 (Protein Kinase B γ) Which Contains the Regulatory Serine Phosphorylation Site," Biochemical and Biophysical Research Comm, (1999) Vol. 257:906-910	
	57	STEPHENS, L., et al. "Protein Kinase B Kinases That Mediate Phosphatidylinositol 3,4,5-Trisphosphate Dependent Activation of Protein Kinase B", Science (1998) Vol 279:710-714	
	58	MARTE, B.M., et al., "PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond," TIBS (1997) 22:355-358	
	59	EMBL: AF135794 4/9/1999	
	60	EMBL: AF124141 5/7/1999	
	61	EMBL: AF124142 5/7/1999	
	62	EMBL: AJ245709 8/27/1999	
	63	EMBL: D49836 12/29/1995	
	64	EMBL: AL117525 9/15/1999	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.